Multiple Myeloma

New Drug: Talquetamab for Multiple Myeloma

2023-09-23

  • Study

    Multicenter, open-label, single-arm trial
    Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
    Talquetamab-tgvs(n=187); Cohort 1: talquetamab 0.4 mg/kg/weekly (n=100); Cohort 2: talquetamab 0.8 mg/kg/weekly (n=87)


  • Efficacy

    Cohort 1
    ORR:73% [63.2-81.4]
    mDoR: 9.5 mos [6.5-NR]

    Cohort 2
    ORR:73.6% [63-82.4]
    mDoR: NR

  • Safety

    Any grade: CRS (>20%), dysgeusia (>20%), nail disorder (>20%),musculoskeletal pain (>20%), upper respiratory infection (>20%)


    • Article has not yet been published

    Article has not yet been published

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023